Cipla, Eli Lilly and Company enter into strategic partnership in India
4th Oct 2021

Cipla and Eli Lilly and Company (India) -- wholly owned subsidiary of Eli Lilly and Company have entered into strategic partnership in India to enhance the reach of Lilly‚Äôs Diabetes products -- Humalog [Insulin Lispro I.P. (rDNA Origin) injection] and Trulicity (Dulaglutide).  As a part of this agreement, Lilly will transfer its rights in India to sell, promote and distribute the aforesaid two Lilly Diabetes products -- Humalog & Trulicity to Cipla, subject to all regulatory approvals.

Lilly will continue to maintain its existing operating model for the remaining portfolio of products. Cipla will leverage its capabilities and robust distribution strengths to engage healthcare professionals and expand access to these treatments for patients who need them.

Cipla is a global pharmaceutical company which uses cutting edge technology and innovation to meet the everyday needs of all patients.